Lexology February 21, 2024
Speaking at the J.P. Morgan Healthcare Conference this year, Hogan Lovells life sciences regulatory partners Lowell Zeta and Blake Wilson, were joined by Greenleaf Health’s Kalah Auchincloss, Executive Vice President, Regulatory Compliance, who served in senior roles at the U.S. Food and Drug Administration (FDA) and Wilson Bryan, Executive Vice President and former Director of FDA’s Office of Tissues and Advanced Therapies (OTAT), who oversaw the agency’s regulation of cell and gene therapies. Informing stakeholders’ strategic investment decisions, this dynamic panel discussed challenges and opportunities associated with advancing precision medicine and innovative diagnostics to ensure patient access, with a focus on FDA’s priorities in the current election year. As industry looks ahead into 2024 with skeptical excitement for increased investment...
Today's Sponsors
Today's Sponsor